EPIMAB BIOTHERAPEUTICS

epimab-biotherapeutics-logo

EpimAb Biotherapeutics is a privately owned biopharmaceutical company dedicated to generating novel bi-specific antibody therapeutics based on its proprietary FIT-Ig (Fabs-In-Tandem) platform. Monoclonal antibodies have transformed the treatment of human diseases, including inflammatory and autoimmune diseases, cancer, severe infections and many rare conditions over the course of the past two decades. Bi-specific antibodies are engineered from two different monoclonal antibodies and combine t... heir key features into one molecule. As a novel drug class, bi-specifics provide additional options for the treatment of many life-threatening diseases such as cancer. However, even minor modifications to any pharmaceutically active biologic such as an antibody can significantly change the properties critical to its development, such as its binding properties, the pharmacokinetics, its stability, solubility and the ability to produce it in sufficient quantities at reasonable costs. This challenge has prevented a majority of bi-specific antibodies of potential interest to scientists and clinicians from advancing into clinical development because their drug-like features were compromised. Thus, the need for a new generation of bi-specific antibody therapeutics in the pharmaceutical industry remains high.

#SimilarOrganizations #People #Financial #Website #More

EPIMAB BIOTHERAPEUTICS

Social Links:

Industry:
Biopharma Biotechnology Health Care Therapeutics

Founded:
2015-01-01

Address:
Shanghai, Shanghai, China

Country:
China

Website Url:
http://www.epimab.com

Total Employee:
11+

Status:
Active

Contact:
+49 (0) 15226107621

Total Funding:
219 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Domain Not Resolving Apache Apple Mobile Web App Capable DigiCert SSL Apple Mobile Web App Status Bar Style Java EE


Similar Organizations

accent-therapeutics-logo

Accent Therapeutics

Accent Therapeutics is a biopharmaceutical company.

alpha-biopharma-logo

Alpha Biopharma

Alpha Biophama is a clinical stage biopharmaceutical company.

arbutus-biopharma-logo

Arbutus Biopharma

Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.

arkuda-therapeutics-logo

Arkuda Therapeutics

Arkuda Therapeutics is a pharmaceutical company.

sio-gene-therapies-logo

Sio Gene Therapies

Sio Gene Therapies is a clinical-stage biopharmaceutical company.

context-therapeutics-logo

Context Therapeutics

Context Therapeutics is a clinical-stage biopharmaceutical company.

frontier-biotechnologies-logo

Frontier Biotechnologies

Frontier Biotechnologies is a commercial-stage bio-pharmaceutical company.


Current Advisors List

not_available_image

Sungwon Song Board Member @ EpimAb Biotherapeutics
Board_member
2021-03-01

not_available_image

Tony Rong Board Member @ EpimAb Biotherapeutics
Board_member
2021-03-01

cheng-xing_image

Cheng Xing Board Of Directors @ EpimAb Biotherapeutics
Board_member

not_available_image

Dongfang Li Board Of Directors @ EpimAb Biotherapeutics
Board_member

robert-kamen_image

Robert Kamen Board Member @ EpimAb Biotherapeutics
Board_member
2015-05-01

Current Employees Featured

chengbin-wu_image

Chengbin Wu
Chengbin Wu CEO @ EpimAb Biotherapeutics
CEO
2016-05-01

bin-peng_image

Bin Peng
Bin Peng CMO @ EpimAb Biotherapeutics
CMO

stephan-lensky_image

Stephan Lensky
Stephan Lensky COO, CBO @ EpimAb Biotherapeutics
COO, CBO
2015-07-01

Founder


chengbin-wu_image

Chengbin Wu

Investors List

hony-capital_image

Hony Capital

Hony Capital investment in Series C - EpimAb Biotherapeutics

sherpa-venture-capital_image

Sherpa Venture Capital

Sherpa Venture Capital investment in Series C - EpimAb Biotherapeutics

cormorant-asset-management_image

Cormorant Asset Management

Cormorant Asset Management investment in Series C - EpimAb Biotherapeutics

miraeasset-financial-group_image

MiraeAsset Financial Group

MiraeAsset Financial Group investment in Series C - EpimAb Biotherapeutics

sdic-fund-management_image

SDIC Fund Management

SDIC Fund Management investment in Series C - EpimAb Biotherapeutics

hidragon-capital_image

Hidragon Capital

Hidragon Capital investment in Series C - EpimAb Biotherapeutics

cmbi-international-capital-corporation_image

CMB International Capital Corporation

CMB International Capital Corporation investment in Series C - EpimAb Biotherapeutics

decheng-capital_image

Decheng Capital

Decheng Capital investment in Series C - EpimAb Biotherapeutics

adrian-cheng-8ec7_image

Adrian Cheng

Adrian Cheng investment in Series C - EpimAb Biotherapeutics

shangbay-capital_image

Shangbay Capital

Shangbay Capital investment in Series C - EpimAb Biotherapeutics

Official Site Inspections

http://www.epimab.com

  • Host name: 112.65.179.211
  • IP address: 112.65.179.211
  • Location: Shanghai China
  • Latitude: 31.0449
  • Longitude: 121.4012
  • Timezone: Asia/Shanghai

Loading ...

More informations about "EpimAb Biotherapeutics" on Search Engine